Product Description
Mechanisms of Action: 5-HT Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: France | India | Lithuania | Malta | Portugal | Slovenia | Spain | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Daniel F Fouladi
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hypoxia|Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant
Phase 3: Spinal Cord Injuries
Phase 2: Obesity|Crohn Disease|Colitis, Ulcerative|Depressive Disorder, Major|Fragile X Syndrome|Asthma, Allergic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
IRB_00132830_R33 | P2 |
Recruiting |
Depressive Disorder, Major |
2026-06-30 |
|
5-HTP only | P3 |
Recruiting |
Spinal Cord Injuries |
2025-06-30 |
|
Kloepfer_1902366300 | P2 |
Recruiting |
Asthma, Allergic |
2024-12-01 |
|
IRB_00132830 | P2 |
Completed |
Depressive Disorder, Major |
2023-08-01 |